Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05125224 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 163,720
- Enrollment target
NCT05125224: Completed study, sponsored by Brigham and Women's Hospital.
NCT05125224 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 163,720 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05125224 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 163,720 participants
- Enrollment target
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Primary Outcome
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Interventions
- DRUG Hydrochlorothiazide
- DRUG Dihydropyridine calcium channel blocker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163,720 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2023-12-31 |
What the finished NCT05125224 record still lists
NCT05125224 is an observational study that tracks outcomes without assigning an intervention. Its 163,720 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Hydrochlorothiazide is the first listed.
NCT05125224 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05125224 about?
NCT05125224 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT05125224?
This trial is currently completed. The enrollment target is 163,720 participants. The study started on 2021-10-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05125224?
The interventions under investigation include: Hydrochlorothiazide (DRUG), Dihydropyridine calcium channel blocker (DRUG).
Who is sponsoring clinical trial NCT05125224?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI